Autoantibody to vasoactive intestinal peptide in human circulation.
In a radioassay for Vasoactive Intestinal Peptide (VIP)-binding, eight out of 33 plasma samples from healthy human subjects exhibited specific binding ranging from 2.6% to 46.7% of total [125 I]VIP. This binding was competitively displaced by unlabeled VIP. The structurally homologous peptides, Peptide Histidine Isoleucine (PHI) and secretin, were, respectively, 72-fold and 413-fold less potent than VIP in displacing bound [125 I]VIP, whereas the unrelated peptides, neurotensin, eledoisin, bombesin and metenkephalin, were without effect on the binding. The antibody nature of the VIP-binding factor was suggested by its precipitation with ammonium sulfate, attenuation after absorption with Staphylococcus aureus preparations, precipitation with antisera against human IgG and IgM, and coelution with standard IgG and IgM on anion-exchange and high-performance gel-filtration columns. Pepsin treatment of purified IgG fraction yielded a VIP-binding species with apparent molecular weight of 108 +/- 13 kDa that was precipitated by antiserum against the F(ab)2 fragment of the IgG molecule. These results demonstrate the existence in some human plasmas of an autoantibody that binds VIP.
D000918:Antibody Specificity; D001323:Autoantibodies / Q000032:analysis*; D006801:Humans; D009419:Nerve Tissue Proteins / Q000276:immunology; D010451:Peptide PHI; D010455:Peptides / Q000276:immunology; D012633:Secretin / Q000276:immunology; D014660:Vasoactive Intestinal Peptide / Q000276:immunology*
D001323:Autoantibodies; D009419:Nerve Tissue Proteins; D010451:Peptide PHI; D010455:Peptides; D012633:Secretin; D014660:Vasoactive Intestinal Peptide